Tag Archives: India
Supreme Court to decide on women’s right to dance in bars
9 May 2013, New Delhi: The Supreme Court today reserved its decision on the constitutionality of the ban on dance performances in bars in Maharashtra imposed under the Bombay Police (Amendment) Act of 2005. Introduced in August 2005, section 33A
India’s patent case victory rattles Big Pharma
Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s Supreme Court’s dismissal of Swiss pharma giant
India’s Patently Wise Decision
The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer. If other developing countries follow India’s
Attack on affordable medicines continues in EU-India trade negotiations
Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world 10 April, 2013, New Delhi- Thousands of people living with HIV, cancer patient groups & public health activists rallied
Apex court right to reject Novartis’s attempt
Novartis threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent
South Korean civil society groups welcome the ruling of the Supreme Court of India
[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and
Strictest patent laws will foster genuine innovation
In 2005, as the Indian Parliament debated at length the impact of complying with the WTO’s TRIPS Agreement, one issue was uppermost in their minds; the impact of granting patents on access to affordable generic medicines. And, the one medicine
Glivec ruling: Putting patients before profits
Supreme Court’s verdict on Glivec benefits not just millions in India, but across the developing world Anand Grover Novartis’s assertions that the ruling will affect investment or future innovations have been belied time and again, including at the World Health
